Navigation Links
Acne Cream Not Linked to Raised Death Risk
Date:1/23/2009

Analysis of VA study that was halted early says retinoid tretinoin not the culprit

FRIDAY, Jan. 23 (HealthDay News) -- A new analysis suggests that an acne medication that was tried as a possible skin cancer preventative in a 1998 clinical trial probably did not cause the deaths of several veterans participating in that research.

The earlier study was halted six months early, when a increased risk of death was seen in those using retinoid tretinoin cream when compared to those taking a placebo.

However, a closer look at the data from that trial did not uncover a definitive link between the treatment and an increased risk of death.

"We didn't see any evidence for a cause-and-effect relationship," said Dr. Martin Weinstock, chief of dermatology at VA Medical Center in Providence, R.I., and a professor of dermatology and community health at Brown University, also in Providence.

Weinstock was lead author of the latest analysis, which was published in the January issue of the Archives of Dermatology and was funded by the U.S. Department of Veterans Affairs.

"This shouldn't change clinical practice, and it's not going to change my clinical practice," added Dr. Jonette Keri, an assistant professor of dermatology and cutaneous surgery at the University of Miami Miller School of Medicine and chief of dermatology at the Miami VA Hospital. "I think it's a very safe medicine with a lot of benefits."

Keri was one of the investigators on the original study, known as the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC). The concept was to investigate whether a cream containing a high dose of retinoid tretinoin could keep certain types of skin cancer, particularly basal and squamous cell malignances, at bay in high-risk people.

"Systemic retinoids are known to be effective in reducing the risk of certain carcinomas in certain high-risk contexts such as renal transplant recipients," Weinstock explained. "The question was, might they be effective in preventing skin cancer not in a super high-risk population but a high-risk population.

The study enrolled 1,131 veterans (average age 71), almost all of them male. Participants were randomly assigned to apply a cream containing 0.1 percent tretinoin (the highest dose commercially available) or a placebo cream to their face and ears twice a day.

Patients with a high risk of death within three years, including prior cancer or other serious medical condition such as advanced heart disease, were excluded from the trial.

The trial was halted in May 2004 due to unexpectedly higher death rates in the treatment arm of the study (82 died in the treatment arm, vs. 53 in the placebo arm).

But the absence of a dose-response relationship, several different causes of death, and minimal absorption of the cream indicated that tretinoin was not responsible for the increased mortality, the authors of the new analysis stated. Also, whether or not the veterans smoked or had smoked was not verified, and retinoids have been associated with an increased risk of death among smokers.

Another thing to consider, the study authors pointed out, is that the trial was done in older people, a group that has not specifically been studied in relation to this issue.

OrthoNeutrogena, the makers of Retin-A, concurred with the findings. "The results of this study did not demonstrate a causal relationship between treatment with Tretinoin and mortality," the company said in a statement. "The study author findings are consistent with OrthoNeutrogena's systematic review of available published literature, which did not find evidence of a relationship between any systemic adverse events and topical Tretinoin."

More information

The U.S. National Library of Medicine has more on tretinoin.



SOURCES: Martin A. Weinstock, M.D., Ph.D., chief, dermatology, VA Medical Center, and professor, dermatology and community health, Brown University, Providence, R.I.; Jonette Keri, M.D., Ph.D., assistant professor, dermatology and cutaneous surgery, University of Miami Miller School of Medicine, and chief, dermatology, Miami VA Hospital; Jan. 23, 2009, statement, OrthoNeutrogena; January 2009, Archives of Dermatology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. In Time, Cream Might Prevent Herpes Transmission
2. Kroger Recalls Select Ice Cream Products Due to Possible Health Risk
3. FDA Approves Durameds Synthetic Conjugated Estrogens-A Vaginal Cream
4. Wrinkle Cream Reviews Site Reveals a Winner for 2008's Best Wrinkle Creams : Wrinkle Cream reviewssite, WrinkleBest.com has released the Editor's Choice for Best Wrinkle Cream of 2008
5. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause
6. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse
7. Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market
8. Sun Safety Champions Team Up With LPGA Tour Pro Paula Creamer
9. Tomlinson Attributes Rebound to Anti-Inflammatory Cream
10. Estrogen Cream No Match for Sun-Damaged Skin
11. Clean, Chemical-Free Eye Cream Evening Primrose Oil: The Puffy-Eye Cure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Acne Cream Not Linked to Raised Death Risk
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... With the ... created the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about ... Dentistry, the dental implant and prosthetic market in the U.S. is projected to reach ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., ... for adherence to the highest standards of trauma, maternity, cancer and chronic obstructive ... president and CEO, Dr. Daniel Messina. , Among the recognitions, the American College ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) ... per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks ... (WCRI) . , According to the study, medical payments per claim in California decreased ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 Bodycad announced it ... improving the accuracy, reproducibility and speed for 3D ... and small bone orthopaedic applications. These patents are ... personalized orthopaedic restorations based on each patient,s distinct ... the company harnesses the world,s first suite of ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... , Dec. 8, 2016 True ... that brings leading-edge laboratory services and management expertise ... States , allowing more doctors and patients ... care management solutions. Logo - ... Hospital systems, under pressure to contain costs, ...
Breaking Medicine Technology: